# Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

> **NCT03470337** · PHASE3 · COMPLETED · sponsor: **Mucos Pharma GmbH & Co. KG** · enrollment: 100 (actual)

## Conditions studied

- Thrombophlebitis Leg

## Interventions

- **DRUG:** Phlogenzym
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03470337
- **Lead sponsor:** Mucos Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-09
- **Primary completion:** 1997-06
- **Final completion:** 1997-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470337, "Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03470337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*